- Home
- HMY vs LNTH Comparison
HMY vs LNTH Comparison
Compare HMY & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- LNTH
- Stock Information
- Founded
- HMY 1950
- LNTH 1956
- Country
- HMY South Africa
- LNTH United States
- Employees
- HMY N/A
- LNTH N/A
- Industry
- HMY Precious Metals
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HMY Basic Materials
- LNTH Health Care
- Exchange
- HMY Nasdaq
- LNTH Nasdaq
- Market Cap
- HMY 7.5B
- LNTH 7.5B
- IPO Year
- HMY N/A
- LNTH 2015
- Fundamental
- Price
- HMY $14.20
- LNTH $79.80
- Analyst Decision
- HMY Sell
- LNTH Strong Buy
- Analyst Count
- HMY 2
- LNTH 5
- Target Price
- HMY $6.60
- LNTH $133.80
- AVG Volume (30 Days)
- HMY 5.7M
- LNTH 1.4M
- Earning Date
- HMY 02-04-2016
- LNTH 05-07-2025
- Dividend Yield
- HMY 1.03%
- LNTH N/A
- EPS Growth
- HMY 16.30
- LNTH N/A
- EPS
- HMY 0.88
- LNTH 3.53
- Revenue
- HMY $3,553,951,394.00
- LNTH $1,536,699,000.00
- Revenue This Year
- HMY $23.09
- LNTH $4.96
- Revenue Next Year
- HMY $14.74
- LNTH $10.25
- P/E Ratio
- HMY $16.04
- LNTH $22.59
- Revenue Growth
- HMY 16.84
- LNTH 12.53
- 52 Week Low
- HMY $7.97
- LNTH $74.34
- 52 Week High
- HMY $18.77
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- HMY 43.51
- LNTH 29.31
- Support Level
- HMY $13.62
- LNTH $77.01
- Resistance Level
- HMY $14.50
- LNTH $80.17
- Average True Range (ATR)
- HMY 0.45
- LNTH 3.61
- MACD
- HMY -0.30
- LNTH -2.34
- Stochastic Oscillator
- HMY 17.64
- LNTH 6.93
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.